Analysts expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will post $1.10 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Xeris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.30 million and the lowest estimate coming in at $890,000.00. Xeris Pharmaceuticals posted sales of $800,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 37.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, March 4th.
According to Zacks, analysts expect that Xeris Pharmaceuticals will report full year sales of $1.83 million for the current year, with estimates ranging from $1.46 million to $2.20 million. For the next financial year, analysts forecast that the business will report sales of $22.69 million, with estimates ranging from $22.17 million to $23.20 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last posted its earnings results on Thursday, November 7th. The company reported ($1.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.01. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million.
In other Xeris Pharmaceuticals news, insider Paul R. Edick bought 17,935 shares of Xeris Pharmaceuticals stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $8.55 per share, with a total value of $153,344.25. Following the purchase, the insider now directly owns 172,935 shares in the company, valued at approximately $1,478,594.25. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Steven Prestrelski sold 27,700 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $9.00, for a total value of $249,300.00. Corporate insiders own 7.43% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Invesco Ltd. purchased a new stake in shares of Xeris Pharmaceuticals during the second quarter worth approximately $11,440,000. FMR LLC increased its position in shares of Xeris Pharmaceuticals by 29.9% during the first quarter. FMR LLC now owns 2,963,018 shares of the company’s stock worth $29,749,000 after purchasing an additional 682,050 shares in the last quarter. BlackRock Inc. increased its position in shares of Xeris Pharmaceuticals by 19.5% during the second quarter. BlackRock Inc. now owns 2,138,781 shares of the company’s stock worth $24,468,000 after purchasing an additional 348,308 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Xeris Pharmaceuticals during the third quarter worth approximately $918,000. Finally, Vanguard Group Inc. increased its position in shares of Xeris Pharmaceuticals by 7.1% during the second quarter. Vanguard Group Inc. now owns 1,219,153 shares of the company’s stock worth $13,947,000 after purchasing an additional 81,209 shares in the last quarter. 66.37% of the stock is owned by institutional investors and hedge funds.
Shares of XERS stock traded up $0.14 during trading hours on Friday, reaching $8.94. 125,806 shares of the company’s stock were exchanged, compared to its average volume of 196,196. The stock’s fifty day moving average price is $8.34 and its two-hundred day moving average price is $10.21. The stock has a market cap of $241.07 million, a PE ratio of -1.79 and a beta of -0.39. Xeris Pharmaceuticals has a 1 year low of $6.85 and a 1 year high of $20.90. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 1.33.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Article: What is a front-end load?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.